Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes
(2006) In Haematologica 91(5). p.667-670- Abstract
- The present study evaluated the combination of antithymocyte globulin (ATG) and cyclosporine A (CsA) in patients with low-risk myelodysplastic syndromes. Twenty patients (17 with refractory anemia and 3 with refractory anemia with excess blasts) received treatment with rabbit-ATG plus CsA. The overall response rate was 30% (6/20); three of the six responders had a complete response. The responses lasted 2-58 months, with two patients still being in complete remission at 42 and 58 months. Short-lasting cytogenetic remissions were achieved in two patients. ATG was poorly tolerated in patients over 70 years of age. Four out of 20 patients progressed to acute myeloid leukemia within a year. We conclude that immunosuppressive treatment may be a... (More)
- The present study evaluated the combination of antithymocyte globulin (ATG) and cyclosporine A (CsA) in patients with low-risk myelodysplastic syndromes. Twenty patients (17 with refractory anemia and 3 with refractory anemia with excess blasts) received treatment with rabbit-ATG plus CsA. The overall response rate was 30% (6/20); three of the six responders had a complete response. The responses lasted 2-58 months, with two patients still being in complete remission at 42 and 58 months. Short-lasting cytogenetic remissions were achieved in two patients. ATG was poorly tolerated in patients over 70 years of age. Four out of 20 patients progressed to acute myeloid leukemia within a year. We conclude that immunosuppressive treatment may be a therapeutic option for selected patients with myelodysplastic syndrome. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/408643
- author
- organization
- publishing date
- 2006
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- cyclosporine A, MDS, ATG, treatment
- in
- Haematologica
- volume
- 91
- issue
- 5
- pages
- 667 - 670
- publisher
- Ferrata Storti Foundation
- external identifiers
-
- wos:000237684000017
- pmid:16670072
- scopus:33744492061
- ISSN
- 1592-8721
- language
- English
- LU publication?
- yes
- id
- 29fba6d1-d0c3-43f3-9a80-98266d22b724 (old id 408643)
- alternative location
- http://www.haematologica.org/backissues/details.php?id=38228
- date added to LUP
- 2016-04-01 17:10:00
- date last changed
- 2022-01-29 00:50:03
@article{29fba6d1-d0c3-43f3-9a80-98266d22b724,
abstract = {{The present study evaluated the combination of antithymocyte globulin (ATG) and cyclosporine A (CsA) in patients with low-risk myelodysplastic syndromes. Twenty patients (17 with refractory anemia and 3 with refractory anemia with excess blasts) received treatment with rabbit-ATG plus CsA. The overall response rate was 30% (6/20); three of the six responders had a complete response. The responses lasted 2-58 months, with two patients still being in complete remission at 42 and 58 months. Short-lasting cytogenetic remissions were achieved in two patients. ATG was poorly tolerated in patients over 70 years of age. Four out of 20 patients progressed to acute myeloid leukemia within a year. We conclude that immunosuppressive treatment may be a therapeutic option for selected patients with myelodysplastic syndrome.}},
author = {{Broliden, PA and Dahl, IM and Hast, R and Johansson, Bertil and Juvonen, E and Kjeldsen, L and Porwit-MacDonald, A and Sjoo, M and Tangen, JM and Uggla, B and Oberg, G and Hellstrom-Lindberg, E}},
issn = {{1592-8721}},
keywords = {{cyclosporine A; MDS; ATG; treatment}},
language = {{eng}},
number = {{5}},
pages = {{667--670}},
publisher = {{Ferrata Storti Foundation}},
series = {{Haematologica}},
title = {{Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes}},
url = {{http://www.haematologica.org/backissues/details.php?id=38228}},
volume = {{91}},
year = {{2006}},
}